India, March 18 -- Innovent Biologics Inc. and HUTCHMED (China) Limited announced that the FRUSICA-2 Phase 2/3 clinical trial, which evaluated sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China, has met its primary endpoint of progression free survival per RECIST 1.1 as assessed by blinded independent central review (BICR).
The companies noted that the combination of sintilimab and fruquintinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates...